Strain Report - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Strain: LEW/Crl

Symbol: LEW/Crl
Strain: LEW
Substrain: Crl
Full Name: Lewis
RGD ID: 737932
Citation ID: RRID:RGD_737932
Ontology ID: RS:0000509
Also known as: MDC-01-40; LEW/CrlBR
Type: inbred
Source: Charles River Laboratories
Origin: Developed by Dr. Lewis from Wistar stock in the early 1950s. To Charles River from Tulane in 1970 at F34.
Last Known Status: Unknown





Disease Annotations     Click to see Annotation Detail View


Phenotype Values via PhenoMiner     Click to see Annotation Detail View
Options:  View chart  |  Download data table  |  View expanded data table

Clinical Measurement
heart rate
left ventricular diastolic blood pressure
left ventricular systolic blood pressure
mean arterial blood pressure
body weight
body temperature
left ventricular developed pressure
red blood cell count
blood hemoglobin level
blood neutrophil count
blood lymphocyte count
blood monocyte count
blood eosinophil count
hematocrit
mean corpuscular volume
plasma anion gap
heart wet weight
heart weight to body weight ratio
lung dry weight to body weight ratio
heart right ventricle weight to left ventricle weight ratio
plasma renin activity level
minute ventilation
arterial blood flow rate
tidal volume
partial pressure of blood carbon dioxide (Pco2)
percent change in ventilation
respiration rate
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
absolute change in partial pressure of blood carbon dioxide
absolute change in partial pressure of blood oxygen
absolute change in blood pH
serum total cholesterol level
total white blood cell count
serum total bilirubin level
blood pH
partial pressure of blood oxygen
serum bicarbonate level
serum chloride level
serum potassium level
serum sodium level
serum calcium level
percent change in respiration rate
percent change in tidal volume
absolute change in mean arterial blood pressure
absolute change in heart rate
plasma creatinine level
serum phosphate level
serum glucose level
serum albumin level
serum alanine aminotransferase activity level
serum alkaline phosphatase activity level
serum aspartate aminotransferase activity level
serum urea nitrogen level
serum total protein level
time to onset of heart contraction
time to peak heart contraction
heart contraction pressure
heart left ventricle infarction weight to total heart left ventricle weight ratio
absolute change in body temperature
calculated pulmonary vascular resistance normalized to body weight
FAPGG metabolism-surface area product
methylene blue metabolism-surface area product without auto-oxidation
methylene blue metabolism-surface area product after auto-oxidation
methylene blue to FAPGG metabolism-surface area product ratio
dose of methacholine at which pulmonary conductance is half its pretreatment value
fractional change in blood vessel diameter per unit change in intravascular pressure
concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50)
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50)
concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)
concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)
maximum contractile force per wet weight of aorta
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
percent change in heart rate
percent change in arterial blood flow rate
percent change in left ventricular developed pressure
percent change in left ventricular systolic blood pressure
urine total protein excretion rate
urine albumin excretion rate
urine sodium excretion rate
creatinine clearance
heart effluent lactate dehydrogenase activity level normalized to heart weight
serum globulin level
number of individuals in a study population displaying Pasteurellaceae infection at a point in time
number of individuals in a study population displaying Haemophilus H21 infection at a point in time
number of individuals in a study population displaying Haemophilus H35 infection at a point in time
number of individuals in a study population displaying Pasteurella pneumotropica infection at a point in time

References


Region

Strain QTL Data
Symbol Name Trait
Aia10 Adjuvant induced arthritis QTL 10 joint integrity trait   (VT:0010548)    
Aia11 Adjuvant induced arthritis QTL 11 joint integrity trait   (VT:0010548)    
Aia12 Adjuvant induced arthritis QTL 12 joint integrity trait   (VT:0010548)    
Aia13 Adjuvant induced arthritis QTL 13 joint integrity trait   (VT:0010548)    
Aia14 Adjuvant induced arthritis QTL 14 joint integrity trait   (VT:0010548)    
Aia15 Adjuvant induced arthritis QTL 15 joint integrity trait   (VT:0010548)    
Aia16 Adjuvant induced arthritis QTL 16 joint integrity trait   (VT:0010548)    
Aia17 Adjuvant induced arthritis QTL 17 joint integrity trait   (VT:0010548)    
Aia18 Adjuvant induced arthritis QTL 18 joint integrity trait   (VT:0010548)    
Aia19 Adjuvant induced arthritis QTL 19 joint integrity trait   (VT:0010548)    
Aia20 Adjuvant induced arthritis QTL 20 joint integrity trait   (VT:0010548)    
Aia21 Adjuvant induced arthritis QTL 21 joint integrity trait   (VT:0010548)    
Aia22 Adjuvant induced arthritis QTL 22 joint integrity trait   (VT:0010548)    
Aia23 Adjuvant induced arthritis QTL 23 joint integrity trait   (VT:0010548)    
Aia24 Adjuvant induced arthritis QTL 24 joint integrity trait   (VT:0010548)    
Aia25 Adjuvant induced arthritis QTL 25 joint integrity trait   (VT:0010548)    
Aia26 Adjuvant induced arthritis QTL 26 joint integrity trait   (VT:0010548)    
Aia27 Adjuvant induced arthritis QTL 27 joint integrity trait   (VT:0010548)    
Aia6 Adjuvant induced arthritis QTL 6 joint integrity trait   (VT:0010548)    
Aia7 Adjuvant induced arthritis QTL 7 joint integrity trait   (VT:0010548)    
Aia8 Adjuvant induced arthritis QTL 8 joint integrity trait   (VT:0010548)    
Aia9 Adjuvant induced arthritis QTL 9 joint integrity trait   (VT:0010548)    
Ginf1 Gastrointestinal inflammation QTL 1 cecum mucosa thickness   (VT:0010234)    
Ginf2 Gastrointestinal inflammation QTL 2 liver integrity trait   (VT:0010547)    
Ginf3 Gastrointestinal inflammation QTL 3 liver integrity trait   (VT:0010547)    
Livw3 Liver weight QTL 3 liver mass   (VT:0003402)    
Wbc3 White blood cell count QTL 3 leukocyte quantity   (VT:0000217)    
Wbc4 White blood cell count QTL 4 leukocyte quantity   (VT:0000217)    
Wbc5 White blood cell count QTL 5 leukocyte quantity   (VT:0000217)    
Damaging Variants
Number of Damaging Variants
SampleRnor_6.0Rnor_5.0RGSC_v3.4
LEW/Crl (ICL) 623
LEW/Crl (KNAW) 568
LEW/Crl (RGD) 866
LEW/Crl (2019) 2508
LEW/Crl (2019)


Additional Information

RGD Curation Notes
Note Type Note Reference
strain_phys_biochem This strain was used for genotyping candidate single nucleotide polymorphisms; SNPs obtained from this study can be found in NCBI dbSNP under accession numbers ss12535137 - ss12568440, ss12588074 - ss12588105 or Cuppen Group 737879